NASDAQ: SLDBSolid Biosciences Inc Stock
$7.07-0.29 (-3.94%)
Updated Jun 16, 2026
SLDB Price
$7.07
Fair Value Price
$0.44
Market Cap
$696.04M
52 Week Low
$3.79
52 Week High
$8.87
P/E
-3.63x
P/B
1.86x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$191.78M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
-$172M
Beta
1.37
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
SLDB Overview
Solid Biosciences Inc. is an American biotechnology firm dedicated to creating therapeutic solutions for Duchenne Muscular Dystrophy (DMD). Its most advanced experimental drug, SGT-001, is a gene transfer treatment currently in Phase I/II clinical trials, designed to encourage the production of functional dystrophin protein in patients' muscles. The company is also progressing with SGT-003, which represents a next-generation gene transfer therapy intended for DMD. Beyond specific drug candidates, Solid Biosciences is actively developing innovative platform technologies, such as "dual gene expression," a technique that allows for multiple therapeutic genes to be bundled into a single viral vector, and researching new capsid designs. The company maintains a strategic alliance through a collaboration and license agreement with Ultragenyx Pharmaceutical Inc., focusing on the joint development and market introduction of novel gene therapies for Duchenne Muscular Dystrophy. Founded in 2013, Solid Biosciences Inc. conducts its operations from its headquarters in Cambridge, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SLDB's potential to beat the market
FStrong Sell
- Stocks with a Zen Rating of Strong Sell (F) had an average loss of -8.02% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
SLDB
Ranked#422 of 462
Ranked#422 of 462
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $226.88 | A | |
| $52.10 | A | |
| $16.22 | A |
Be the first to know about important SLDB news, forecast changes, insider trades & much more!
SLDB News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SLDB scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SLDB ($7.07) is overvalued by 1,496.99% relative to our estimate of its Fair Value price of $0.44 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
SLDB ($7.07) is not significantly undervalued (1,496.99%) relative to our estimate of its Fair Value price of $0.44 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
SLDB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more SLDB due diligence checks available for Premium users.
Valuation
SLDB fair value
Fair Value of SLDB stock based on Discounted Cash Flow (DCF)
Price
$7.07
Fair Value
$0.44
Overvalued by
1,496.99%
SLDB ($7.07) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
SLDB ($7.07) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
SLDB is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
SLDB price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.63x
Industry
16.03x
Market
13.25x
SLDB price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.86x
Industry
4.86x
SLDB is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SLDB's financial health
Profit margin
Revenue
$0.0
Net Income
-$56.7M
Profit Margin
0%
SLDB's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$422.9M
Liabilities
$48.8M
Debt to equity
0.13
SLDB's short-term assets ($396.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SLDB's short-term assets ($396.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SLDB's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
SLDB's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$47.2M
Investing
$44.8M
Financing
$239.0M
SLDB's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SLDB vs Biotech Stocks
Solid Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.